Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007.

[1]  R. Tiwari,et al.  (www.interscience.wiley.com) DOI: 10.1002/sim.3733 Estimating average annual per cent change in trend analysis , 2022 .

[2]  T. Tynes,et al.  Cancer in the Sami population of North Norway, 1970–1997 , 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[3]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[4]  G. W. Snedecor.  Statistical Methods , 1964 .

[5]  S. Fosså,et al.  Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry , 2010, BJU international.

[6]  F. Bray,et al.  Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. , 2007, Journal of the National Cancer Institute.

[7]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[8]  C. Parker.  Active surveillance: towards a new paradigm in the management of early prostate cancer. , 2004, The Lancet. Oncology.

[9]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[10]  D. Gunnell,et al.  International trends in prostate‐cancer mortality in the “PSA era” , 2001, International journal of cancer.

[11]  O. Bratt.  Watching the face of Janus--active surveillance as a strategy to reduce overtreatment for localised prostate cancer. , 2006, European urology.

[12]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[13]  T. H. van der Kwast,et al.  Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. , 2007, European urology.

[14]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[15]  Neil Fleshner,et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.

[16]  Sophie D. Fosså,et al.  Kurativ behandling av prostatakreft i Norge i 1998 og 2001 , 2006 .

[17]  C Metcalfe,et al.  Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study , 2009, British Journal of Cancer.

[18]  T. Tammela,et al.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.

[19]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[20]  Katja Fall,et al.  Reliability of death certificates in prostate cancer patients , 2008, Scandinavian journal of urology and nephrology.

[21]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[22]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[23]  Bjørn Møller,et al.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. , 2009, European journal of cancer.

[24]  Tapio Visakorpi,et al.  Statins and prostate cancer prevention: where we are now, and future directions , 2008, Nature Clinical Practice Urology.

[25]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[26]  Harry J de Koning,et al.  Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). , 2009, European urology.

[27]  Xìao-chun Xu,et al.  Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells , 2008, Cancer Epidemiology Biomarkers & Prevention.

[28]  O. Halvorsen,et al.  Radical retropubic prostatectomy: our experience with the first 54 patients. , 1992, Scandinavian journal of urology and nephrology.

[29]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[30]  Hans Garmo,et al.  Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer , 2011 .

[31]  O. Halvorsen,et al.  [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma]. , 1990, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[32]  P. Nguyen,et al.  Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. , 2003, Carcinogenesis.

[33]  D Gillatt,et al.  Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. , 2003, Health technology assessment.

[34]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Andersen,et al.  Cancer in the Nordic countries, 1981-86. A joint publication of the five Nordic Cancer Registries. , 1992, APMIS. Supplementum.

[36]  V. Beral,et al.  Is the apparent rise in cancer mortality in the elderly real? analysis of changes in certification and coding of cause of death in England and Wales, 1970–1990 , 1995, International journal of cancer.

[37]  T. Wentzel‐Larsen,et al.  Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer , 2006, Acta oncologica.